Cargando…

Formulation and evaluation of pH activated dosage form as minitablets in capsule for delivery of fesoterodine

OBJECTIVES: In the present study, an attempt is made to develop novel multifunctional sustained-release minitablets in a capsule system by film coating Fesoterodine for the treatment of urinary incontinence (increased urinating frequency). METHODOLOGY: The direct compression technique was used to fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Syed, Shoaeb M., Rathi, Pratiksha V., Gawale, Kiran G., Hamde, Dipali C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taibah University 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802851/
https://www.ncbi.nlm.nih.gov/pubmed/35140568
http://dx.doi.org/10.1016/j.jtumed.2021.08.014
_version_ 1784642758396346368
author Syed, Shoaeb M.
Rathi, Pratiksha V.
Gawale, Kiran G.
Hamde, Dipali C.
author_facet Syed, Shoaeb M.
Rathi, Pratiksha V.
Gawale, Kiran G.
Hamde, Dipali C.
author_sort Syed, Shoaeb M.
collection PubMed
description OBJECTIVES: In the present study, an attempt is made to develop novel multifunctional sustained-release minitablets in a capsule system by film coating Fesoterodine for the treatment of urinary incontinence (increased urinating frequency). METHODOLOGY: The direct compression technique was used to formulate the minitablets, and coating was applied using hydroxypropyl methylcellulose (HPMC) phthalate. The pre-formulation study was performed using tools like differential scanning calorimetry (DSC), infrared spectroscopy (IR) and post-formulation parameters such as hardness, thickness, weight variation, uniformity, and drug release. Drug release kinetics were studied for the formulations F1–F11. RESULTS: All the pre- and post-formulation parameters were found to be within the limits. F1 and F2 result in burst release of the drug within 30 minutes. For the F3, F4, and F5 formulations, HPMC phthalate-coated minitablets show almost 100% drug release in 3, 4, and 5 hours, respectively. F6, F7, and F8 (2.5%, 5%, and 10% formaldehyde-coated minitablets, respectively) show drug releases in the small intestine, and the release was prolonged for 24 hours, whereas F9, F10, and F11 (2.5%, 5%, and 10% glutaraldehyde-coated minitablets, respectively) release in the small intestine, but drug release takes more than 20 hours. CONCLUSION: Film-coated minitablets were satisfactorily developed in terms of various post-compression parameters like hardness, thickness, friability, weight variation, and content uniformity. IR and DSC studies revealed no significant drug excipient interactions. HPMC phthalate-coated minitablets released in the buffer, and it was supposed that the drug releases in the intestine, which leads to better absorption and follows Korsmeyer-Peppas release kinetics.
format Online
Article
Text
id pubmed-8802851
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taibah University
record_format MEDLINE/PubMed
spelling pubmed-88028512022-02-08 Formulation and evaluation of pH activated dosage form as minitablets in capsule for delivery of fesoterodine Syed, Shoaeb M. Rathi, Pratiksha V. Gawale, Kiran G. Hamde, Dipali C. J Taibah Univ Med Sci Original Article OBJECTIVES: In the present study, an attempt is made to develop novel multifunctional sustained-release minitablets in a capsule system by film coating Fesoterodine for the treatment of urinary incontinence (increased urinating frequency). METHODOLOGY: The direct compression technique was used to formulate the minitablets, and coating was applied using hydroxypropyl methylcellulose (HPMC) phthalate. The pre-formulation study was performed using tools like differential scanning calorimetry (DSC), infrared spectroscopy (IR) and post-formulation parameters such as hardness, thickness, weight variation, uniformity, and drug release. Drug release kinetics were studied for the formulations F1–F11. RESULTS: All the pre- and post-formulation parameters were found to be within the limits. F1 and F2 result in burst release of the drug within 30 minutes. For the F3, F4, and F5 formulations, HPMC phthalate-coated minitablets show almost 100% drug release in 3, 4, and 5 hours, respectively. F6, F7, and F8 (2.5%, 5%, and 10% formaldehyde-coated minitablets, respectively) show drug releases in the small intestine, and the release was prolonged for 24 hours, whereas F9, F10, and F11 (2.5%, 5%, and 10% glutaraldehyde-coated minitablets, respectively) release in the small intestine, but drug release takes more than 20 hours. CONCLUSION: Film-coated minitablets were satisfactorily developed in terms of various post-compression parameters like hardness, thickness, friability, weight variation, and content uniformity. IR and DSC studies revealed no significant drug excipient interactions. HPMC phthalate-coated minitablets released in the buffer, and it was supposed that the drug releases in the intestine, which leads to better absorption and follows Korsmeyer-Peppas release kinetics. Taibah University 2021-11-09 /pmc/articles/PMC8802851/ /pubmed/35140568 http://dx.doi.org/10.1016/j.jtumed.2021.08.014 Text en © 2021 Taibah University. Production and hosting by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Syed, Shoaeb M.
Rathi, Pratiksha V.
Gawale, Kiran G.
Hamde, Dipali C.
Formulation and evaluation of pH activated dosage form as minitablets in capsule for delivery of fesoterodine
title Formulation and evaluation of pH activated dosage form as minitablets in capsule for delivery of fesoterodine
title_full Formulation and evaluation of pH activated dosage form as minitablets in capsule for delivery of fesoterodine
title_fullStr Formulation and evaluation of pH activated dosage form as minitablets in capsule for delivery of fesoterodine
title_full_unstemmed Formulation and evaluation of pH activated dosage form as minitablets in capsule for delivery of fesoterodine
title_short Formulation and evaluation of pH activated dosage form as minitablets in capsule for delivery of fesoterodine
title_sort formulation and evaluation of ph activated dosage form as minitablets in capsule for delivery of fesoterodine
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802851/
https://www.ncbi.nlm.nih.gov/pubmed/35140568
http://dx.doi.org/10.1016/j.jtumed.2021.08.014
work_keys_str_mv AT syedshoaebm formulationandevaluationofphactivateddosageformasminitabletsincapsulefordeliveryoffesoterodine
AT rathipratikshav formulationandevaluationofphactivateddosageformasminitabletsincapsulefordeliveryoffesoterodine
AT gawalekirang formulationandevaluationofphactivateddosageformasminitabletsincapsulefordeliveryoffesoterodine
AT hamdedipalic formulationandevaluationofphactivateddosageformasminitabletsincapsulefordeliveryoffesoterodine